18 F-FDG PET/CT in the Management of Osteosarcoma
Osteosarcoma is the most common type of primary malignant bone tumor. F-FDG PET/CT is useful for staging, detecting recurrence, monitoring response to neoadjuvant chemotherapy, and predicting prognosis. Here, we review the clinical aspects of osteosarcoma management and assess the role of F-FDG PET/...
Gespeichert in:
| Veröffentlicht in: | Journal of Nuclear Medicine 2023-06, Vol.64 (6), p.842-851 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 851 |
|---|---|
| container_issue | 6 |
| container_start_page | 842 |
| container_title | Journal of Nuclear Medicine |
| container_volume | 64 |
| creator | Oh, Chiwoo Bishop, Michael W Cho, Steve Y Im, Hyung-Jun Shulkin, Barry L |
| description | Osteosarcoma is the most common type of primary malignant bone tumor.
F-FDG PET/CT is useful for staging, detecting recurrence, monitoring response to neoadjuvant chemotherapy, and predicting prognosis. Here, we review the clinical aspects of osteosarcoma management and assess the role of
F-FDG PET/CT, in particular with regard to pediatric and young adult patients. |
| doi_str_mv | 10.2967/jnumed.123.265592 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2967_jnumed_123_265592</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37201958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1138-144a26b55e1e8795523cdd790b7666a2868df6fecb8528352166fd11952e73f83</originalsourceid><addsrcrecordid>eNo1z8FOwzAMgOEIgVgZPAAXlBfoFiezkx5RWQfS0DiUc5W2CWyi7dR0B96eTmUnH6zf8sfYI4iFTEgvD-2pcfUCpFpIQkzkFYsAFcZIpK9ZJIAgRhQ4Y3chHIQQZIy5ZTOlpYAETcQADM_i7GXDP9b5Ms35vuXDt-PvtrVfrnHtwDvPd2FwXbB91TX2nt14-xPcw_-cs89snaev8Xa3eUuft3EFoEwMq5WVVCI6cEYniFJVda0TUWoistKQqT15V5UGpVEogcjXMH4lnVbeqDmD6W7VdyH0zhfHft_Y_rcAUZz5xcQvRn4x8cfmaWqOp_K8uhQXr_oDKDFTkA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>18 F-FDG PET/CT in the Management of Osteosarcoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Oh, Chiwoo ; Bishop, Michael W ; Cho, Steve Y ; Im, Hyung-Jun ; Shulkin, Barry L</creator><creatorcontrib>Oh, Chiwoo ; Bishop, Michael W ; Cho, Steve Y ; Im, Hyung-Jun ; Shulkin, Barry L</creatorcontrib><description>Osteosarcoma is the most common type of primary malignant bone tumor.
F-FDG PET/CT is useful for staging, detecting recurrence, monitoring response to neoadjuvant chemotherapy, and predicting prognosis. Here, we review the clinical aspects of osteosarcoma management and assess the role of
F-FDG PET/CT, in particular with regard to pediatric and young adult patients.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.123.265592</identifier><identifier>PMID: 37201958</identifier><language>eng</language><publisher>United States</publisher><subject>Bone Neoplasms - diagnostic imaging ; Bone Neoplasms - therapy ; Child ; Fluorodeoxyglucose F18 - therapeutic use ; Humans ; Neoplasm Staging ; Osteosarcoma - diagnostic imaging ; Osteosarcoma - therapy ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Radiopharmaceuticals - therapeutic use ; Young Adult</subject><ispartof>Journal of Nuclear Medicine, 2023-06, Vol.64 (6), p.842-851</ispartof><rights>2023 by the Society of Nuclear Medicine and Molecular Imaging.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1138-144a26b55e1e8795523cdd790b7666a2868df6fecb8528352166fd11952e73f83</citedby><cites>FETCH-LOGICAL-c1138-144a26b55e1e8795523cdd790b7666a2868df6fecb8528352166fd11952e73f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37201958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oh, Chiwoo</creatorcontrib><creatorcontrib>Bishop, Michael W</creatorcontrib><creatorcontrib>Cho, Steve Y</creatorcontrib><creatorcontrib>Im, Hyung-Jun</creatorcontrib><creatorcontrib>Shulkin, Barry L</creatorcontrib><title>18 F-FDG PET/CT in the Management of Osteosarcoma</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>Osteosarcoma is the most common type of primary malignant bone tumor.
F-FDG PET/CT is useful for staging, detecting recurrence, monitoring response to neoadjuvant chemotherapy, and predicting prognosis. Here, we review the clinical aspects of osteosarcoma management and assess the role of
F-FDG PET/CT, in particular with regard to pediatric and young adult patients.</description><subject>Bone Neoplasms - diagnostic imaging</subject><subject>Bone Neoplasms - therapy</subject><subject>Child</subject><subject>Fluorodeoxyglucose F18 - therapeutic use</subject><subject>Humans</subject><subject>Neoplasm Staging</subject><subject>Osteosarcoma - diagnostic imaging</subject><subject>Osteosarcoma - therapy</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Positron-Emission Tomography</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Young Adult</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1z8FOwzAMgOEIgVgZPAAXlBfoFiezkx5RWQfS0DiUc5W2CWyi7dR0B96eTmUnH6zf8sfYI4iFTEgvD-2pcfUCpFpIQkzkFYsAFcZIpK9ZJIAgRhQ4Y3chHIQQZIy5ZTOlpYAETcQADM_i7GXDP9b5Ms35vuXDt-PvtrVfrnHtwDvPd2FwXbB91TX2nt14-xPcw_-cs89snaev8Xa3eUuft3EFoEwMq5WVVCI6cEYniFJVda0TUWoistKQqT15V5UGpVEogcjXMH4lnVbeqDmD6W7VdyH0zhfHft_Y_rcAUZz5xcQvRn4x8cfmaWqOp_K8uhQXr_oDKDFTkA</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Oh, Chiwoo</creator><creator>Bishop, Michael W</creator><creator>Cho, Steve Y</creator><creator>Im, Hyung-Jun</creator><creator>Shulkin, Barry L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202306</creationdate><title>18 F-FDG PET/CT in the Management of Osteosarcoma</title><author>Oh, Chiwoo ; Bishop, Michael W ; Cho, Steve Y ; Im, Hyung-Jun ; Shulkin, Barry L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1138-144a26b55e1e8795523cdd790b7666a2868df6fecb8528352166fd11952e73f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Bone Neoplasms - diagnostic imaging</topic><topic>Bone Neoplasms - therapy</topic><topic>Child</topic><topic>Fluorodeoxyglucose F18 - therapeutic use</topic><topic>Humans</topic><topic>Neoplasm Staging</topic><topic>Osteosarcoma - diagnostic imaging</topic><topic>Osteosarcoma - therapy</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Positron-Emission Tomography</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oh, Chiwoo</creatorcontrib><creatorcontrib>Bishop, Michael W</creatorcontrib><creatorcontrib>Cho, Steve Y</creatorcontrib><creatorcontrib>Im, Hyung-Jun</creatorcontrib><creatorcontrib>Shulkin, Barry L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oh, Chiwoo</au><au>Bishop, Michael W</au><au>Cho, Steve Y</au><au>Im, Hyung-Jun</au><au>Shulkin, Barry L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>18 F-FDG PET/CT in the Management of Osteosarcoma</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2023-06</date><risdate>2023</risdate><volume>64</volume><issue>6</issue><spage>842</spage><epage>851</epage><pages>842-851</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><abstract>Osteosarcoma is the most common type of primary malignant bone tumor.
F-FDG PET/CT is useful for staging, detecting recurrence, monitoring response to neoadjuvant chemotherapy, and predicting prognosis. Here, we review the clinical aspects of osteosarcoma management and assess the role of
F-FDG PET/CT, in particular with regard to pediatric and young adult patients.</abstract><cop>United States</cop><pmid>37201958</pmid><doi>10.2967/jnumed.123.265592</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | Journal of Nuclear Medicine, 2023-06, Vol.64 (6), p.842-851 |
| issn | 0161-5505 1535-5667 2159-662X |
| language | eng |
| recordid | cdi_crossref_primary_10_2967_jnumed_123_265592 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Bone Neoplasms - diagnostic imaging Bone Neoplasms - therapy Child Fluorodeoxyglucose F18 - therapeutic use Humans Neoplasm Staging Osteosarcoma - diagnostic imaging Osteosarcoma - therapy Positron Emission Tomography Computed Tomography Positron-Emission Tomography Radiopharmaceuticals - therapeutic use Young Adult |
| title | 18 F-FDG PET/CT in the Management of Osteosarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T14%3A15%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=18%20F-FDG%20PET/CT%20in%20the%20Management%20of%20Osteosarcoma&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Oh,%20Chiwoo&rft.date=2023-06&rft.volume=64&rft.issue=6&rft.spage=842&rft.epage=851&rft.pages=842-851&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.123.265592&rft_dat=%3Cpubmed_cross%3E37201958%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37201958&rfr_iscdi=true |